Ofer Gonen

Ofer Gonen currently works at MediWound Ltd., as Chief Executive Officer from 2022, CLAL Application Center Ltd., as Chairman, Biomedical Instruments Divison of Lionheart Tech, Inc., as Managing Director, CureTech Ltd., as Director from 2013, Clal Life Sciences (CLS) LP, as Director, BioCancell Therapeutics, Inc., as Director, Campus Bio Management Ltd., as Director from 2008, Avraham Pharmaceuticals Ltd., as Director, Campus Bio LLP, as Director, Center Ltd., as Director, and Gamida Cell, Inc., as Director.
Mr. Gonen also formerly worked at Clal Biotechnology Industries Ltd. (Venture Capital), as Chief Executive Officer from 2003 to 2022, Clal Biotechnology Industries Ltd., as Chief Executive Officer from 2017 to 2022, Polyheal Ltd., as Chairman from 2010 to 2014, eXIthera Pharmaceuticals, Inc., as Director, CLS Holdings Plc, as Director, Univo Pharmaceuticals Ltd., as Director, Gamida Cell Ltd., as Independent Director from 2015 to 2022, Andromeda Biotech Ltd., as Director from 2007 to 2014, Thrombotech Ltd., as Director, Braintact Ltd., as Director, Anchiano Therapeutics Ltd., as Director from 2015 to 2020, Cadent Ltd., as Director, Elicio Therapeutics, Inc. (United States), as Independent Director from 2021 to 2022, ColBar LifeScience Ltd., as Director, Cactus Acquisition Corp.
1 Ltd., as Director in 2024, Bank of Israel, as Governor, ARTE Venture Group Ltd., as Partner from 2003 to 2015, Biomedical Investments, as General Manager from 2007 to 2014, and Anatomy Medical Technology Fund, as Managing Partner.
Mr. Gonen received his graduate degree in 1998 from Tel-Aviv University and undergraduate degree in 1994 from The Hebrew University of Jerusalem.